Compare Asana Inc. (ASAN) vs Danaher Corporation (DHR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Asana Inc. vs Danaher Corporation — how do they compare? Asana Inc. trades at $8.94 (market cap $2.13B), while Danaher Corporation trades at $204.23 (market cap $145.83B). The key difference: Danaher Corporation is far larger — about 68.5× Asana Inc.'s market cap, and Danaher Corporation pays a 0.77% dividend while Asana Inc. pays none. Which is the better fit depends on your goals.
| ASAN | DHR | |
|---|---|---|
Market Cap | $2.13B | $145.83B |
Sector | Consumer Cyclical | Health |
52-Week High | $15.19 | $242.05 |
52-Week Low | $5.46 | $161.91 |
Enterprise Value | $1.96B | $168.04B |
Dividend Yield | — | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Asana (ASAN) trades at $9.23, down slightly by 0.32% today. The stock exhibits a bullish technical trend with strong moving average signals, though oscillators indicate overbought conditions. Fundamentally, revenue growth is robust with fiscal 2025 revenue reaching $723.88 million, but the company remains unprofitable with a net loss of $255.54 million. Recent news highlights AI product innovation and a strategic partnership with Norway's sovereign wealth fund, signaling positive business momentum.
The outlook for Asana is mixed. Analyst consensus leans bullish with a $10.33 price target, but persistent losses and intense competition from tech giants pose significant risks. Upside potential hinges on continued revenue growth and path to profitability, while downside risks include margin pressure and execution challenges in a competitive SaaS market.
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Asana Inc.
Asana Inc is a software company. The company provides a platform for work management that helps teams orchestrate work, from daily tasks to cross-functional strategic initiatives. It helps plan marketing campaigns, streamlines processes, manages sales, and manage product launches. Also, the company provides project management and workflow management solutions.
Read more on ASAN →About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →
